News >

S-1 Better Tolerated Than Capecitabine With No Loss of Efficacy in Metastatic Colorectal Cancer

Virginia Powers, PhD
Published: Wednesday, Feb 01, 2017

Robert Jan Kwakman, MD, PhD candidate

Robert Jan Kwakman, MD, PhD candidate

The incidence of hand-foot syndrome (HFS) was decreased following first-line treatment with S-1 compared to capecitabine in patients with metastatic colorectal cancer (mCRC), according to findings from the phase III SALTO study that were presented at the 2017 European Cancer Congress.

= .0008).
Kwakman JJM, Simkens LHJ, Van Rooijen JM, et al. Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group. Presented at: 2017 European Cancer Congress; January 27-30, 2017; Amsterdam, The Netherlands. Abstract 2BA.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication